Modern staging and utility of PET imaging in esophageal cancer management

Kwang Yu Chang, Jang Yang Chang, Joseph Chao, Yun Yen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment. Because correct staging and surveillance of neoadjuvant therapy for esophageal cancer is mandatory for further treatment planning, choosing a modern imaging system is important. The development of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided alternate means of tumor detection distinct from more conventional methods. This modality has extraordinary performance in detecting locoregional lymph node involvement and distant metastatic disease, and has been introduced as a powerful tool in many guidelines. However, some factors still lead to false-negative or -positive results, raising questions of its accuracy. This article discusses the clinical efficacy of PET in staging and surveillance of neoadjuvant therapy in esophageal cancer, comparing its accuracy with conventional imaging modalitles.

Original languageEnglish
Pages (from-to)862-869
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number9
DOIs
Publication statusPublished - Jan 1 2008
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Neoadjuvant Therapy
Fluorodeoxyglucose F18
Positron-Emission Tomography
Neoplasms
Lymph Nodes
Guidelines
Therapeutics

Keywords

  • Esophageal cancer
  • FDG
  • Neoadjuvant therapy
  • PET
  • Staging

ASJC Scopus subject areas

  • Oncology

Cite this

Modern staging and utility of PET imaging in esophageal cancer management. / Chang, Kwang Yu; Chang, Jang Yang; Chao, Joseph; Yen, Yun.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 9, 01.01.2008, p. 862-869.

Research output: Contribution to journalArticle

Chang, Kwang Yu ; Chang, Jang Yang ; Chao, Joseph ; Yen, Yun. / Modern staging and utility of PET imaging in esophageal cancer management. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. 9. pp. 862-869.
@article{c1a0ff5e2ca4425c83d7f91f12bf675d,
title = "Modern staging and utility of PET imaging in esophageal cancer management",
abstract = "Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment. Because correct staging and surveillance of neoadjuvant therapy for esophageal cancer is mandatory for further treatment planning, choosing a modern imaging system is important. The development of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided alternate means of tumor detection distinct from more conventional methods. This modality has extraordinary performance in detecting locoregional lymph node involvement and distant metastatic disease, and has been introduced as a powerful tool in many guidelines. However, some factors still lead to false-negative or -positive results, raising questions of its accuracy. This article discusses the clinical efficacy of PET in staging and surveillance of neoadjuvant therapy in esophageal cancer, comparing its accuracy with conventional imaging modalitles.",
keywords = "Esophageal cancer, FDG, Neoadjuvant therapy, PET, Staging",
author = "Chang, {Kwang Yu} and Chang, {Jang Yang} and Joseph Chao and Yun Yen",
year = "2008",
month = "1",
day = "1",
doi = "10.6004/jnccn.2008.0064",
language = "English",
volume = "6",
pages = "862--869",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Modern staging and utility of PET imaging in esophageal cancer management

AU - Chang, Kwang Yu

AU - Chang, Jang Yang

AU - Chao, Joseph

AU - Yen, Yun

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment. Because correct staging and surveillance of neoadjuvant therapy for esophageal cancer is mandatory for further treatment planning, choosing a modern imaging system is important. The development of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided alternate means of tumor detection distinct from more conventional methods. This modality has extraordinary performance in detecting locoregional lymph node involvement and distant metastatic disease, and has been introduced as a powerful tool in many guidelines. However, some factors still lead to false-negative or -positive results, raising questions of its accuracy. This article discusses the clinical efficacy of PET in staging and surveillance of neoadjuvant therapy in esophageal cancer, comparing its accuracy with conventional imaging modalitles.

AB - Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment. Because correct staging and surveillance of neoadjuvant therapy for esophageal cancer is mandatory for further treatment planning, choosing a modern imaging system is important. The development of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided alternate means of tumor detection distinct from more conventional methods. This modality has extraordinary performance in detecting locoregional lymph node involvement and distant metastatic disease, and has been introduced as a powerful tool in many guidelines. However, some factors still lead to false-negative or -positive results, raising questions of its accuracy. This article discusses the clinical efficacy of PET in staging and surveillance of neoadjuvant therapy in esophageal cancer, comparing its accuracy with conventional imaging modalitles.

KW - Esophageal cancer

KW - FDG

KW - Neoadjuvant therapy

KW - PET

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=56049089162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049089162&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2008.0064

DO - 10.6004/jnccn.2008.0064

M3 - Article

C2 - 18926095

AN - SCOPUS:56049089162

VL - 6

SP - 862

EP - 869

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 9

ER -